Intermittent Interferon Therapy With Post-Dose Gemcitabine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing interferon-based cancer treatments suffer from poor efficacy and significant toxic side effects due to continuous administration, leading to immune cell depletion and reduced therapeutic outcomes.
Innovation Solution
An intermittent administration regimen of interferon-based therapeutic agents combined with an additional anticancer agent, where the anticancer agent is administered after the first administration of interferon-based therapy, allowing for immune cell recovery and enhanced therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If interferon-based therapeutic agent is administered continuously at large doses, then anti-tumor effect is enhanced, but toxic side effects and immune cell depletion increase
Solution Approach 1:
The patent applies periodic action by administering interferon-based therapeutic agents intermittently rather than continuously. The treatment protocol involves multiple treatment courses with intervals between them, allowing immune cells to recover while maintaining therapeutic efficacy. This periodic administration pattern resolves the contradiction by providing anti-tumor effects when needed while avoiding cumulative toxicity and immune cell depletion associated with continuous high-dose administration.
2Duration of action of stationary object
If interferon-based therapeutic agent is administered continuously, then therapeutic coverage is maintained, but immune cell function is depleted
Solution Approach 1:
The patent applies segmentation by dividing continuous interferon administration into discrete treatment courses separated by intervals. Each treatment course provides therapeutic coverage for a specific period, followed by a break that allows immune cell recovery. This segmented approach maintains overall therapeutic coverage across the treatment timeline while preserving immune cell function through periodic recovery periods.
Solution Approach 2:
The patent implements periodic action through structured treatment courses with defined intervals. Multiple treatment courses are administered over time with specific dosing schedules within each course, creating a periodic pattern that sustains therapeutic coverage while allowing immune system recovery between courses, thereby maintaining immune cell function.
3Ease of operation
If interferon-based therapeutic agent is administered alone, then treatment simplicity is maintained, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent applies merging by combining interferon-based therapeutic agents with additional anticancer agents in a coordinated treatment regimen. The interferon agent and anticancer agent are administered according to a specific schedule where the anticancer agent follows the first interferon administration in each treatment course. This combination approach enhances therapeutic efficacy through synergistic effects while maintaining operational simplicity through a structured, protocol-driven administration schedule.
Data Source
AI summary
The present invention relates to the field of biomedicine. Disclosed herein is interferon-based method and pharmaceutical combination for treating cancer. In particular, the present invention relates to an interferon-based method for treating cancer, comprising i) intermittently administering an interferon-based therapeutic agent, and ii) administering an additional anticancer agent, preferably, Gemcitabine, to a subject, wherein said additional anti-cancer agent is administered after the first administration of said intermittent administration of an interferon-based therapeutic agent. The present invention also relates to a pharmaceutical combination for use in said method.